These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10397042)

  • 1. Hormone replacement therapies in women at risk of cardiovascular disease and osteoporosis in South Australia in 1997.
    MacLennan AH; Wilson DH; Taylor AW
    Med J Aust; 1999 Jun; 170(11):524-7. PubMed ID: 10397042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone replacement therapy use over a decade in an Australian population.
    MacLennan AH; Wilson DH; Taylor AW
    Climacteric; 2002 Dec; 5(4):351-6. PubMed ID: 12626214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of coronary heart disease in determining use of hormone replacement therapy in a general practice population.
    Chin BS; Futaba K; Jethwa A; Lip GY
    Int J Clin Pract; 2001 Oct; 55(8):515-8. PubMed ID: 11695070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
    Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
    Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the use of hormone replacement therapy in New Zealand from 1991-1997.
    North FM; Sharples K
    N Z Med J; 2001 Jun; 114(1133):250-3. PubMed ID: 11453344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
    Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
    Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy: a survey of Irish general practitioners.
    Fallon U; Kelleher C
    Ir Med J; 2000; 93(1):10-1, 14. PubMed ID: 10740365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in HRT.
    Teede HJ
    Aust Fam Physician; 2002 May; 31(5):413-8. PubMed ID: 12043543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia.
    Dick SE; DeWitt DE; Anawalt BD
    Am J Manag Care; 2002 Jan; 8(1):95-104; quiz 105-6. PubMed ID: 11814176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal hormone therapy: who now takes it and do they differ from non-users?
    Taylor AW; MacLennan AH; Avery JC
    Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):128-35. PubMed ID: 16638035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and correlates of hormone replacement therapy use among middle-aged Australian women.
    France K; Schofield MJ; Lee C
    Womens Health; 1997; 3(2):121-38. PubMed ID: 9332154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].
    Emons G; Westphalen S
    MMW Fortschr Med; 2002 Feb; 144(9):30-3. PubMed ID: 11921648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy use and menopausal symptoms among women participating in a behavioral lifestyle intervention.
    Boraz MA; Simkin-Silverman LR; Wing RR; Meilahn EN; Kuller LH
    Prev Med; 2001 Aug; 33(2 Pt 1):108-14. PubMed ID: 11493043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of hormone replacement therapy in a population-based cohort of postmenopausal German women. Changes after HERS II and WHI.
    Clanget C; Hinke V; Lange S; Fricke R; Botko R; Pfeilschifter J
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):529-33. PubMed ID: 16235155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
    Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
    Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis and cardiovascular disease: benefit-risk of hormone replacement therapy.
    Sammartino A; Cirillo D; Mandato VD; Di Carlo C; Nappi C
    J Endocrinol Invest; 2005; 28(10 Suppl):80-4. PubMed ID: 16550729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and risk for coronary heart disease. Data from the CORA-study--a case-control study on women with incident coronary heart disease.
    Windler E; Zyriax BC; Eidenmüller B; Boeing H
    Maturitas; 2007 Jul; 57(3):239-46. PubMed ID: 17292571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.